Single-cell RNA-seq analysis of human CSF microglia and myeloid cells in neuroinflammation
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 3, 2019
- Accepted in final form March 10, 2020
- First Published May 5, 2020.
Author Disclosures
- Ekaterina Esaulova, MS*,
- Claudia Cantoni, PhD*,
- Irina Shchukina, MS,
- Konstantin Zaitsev, MS,
- Robert C. Bucelli, MD, PhD,
- Gregory F. Wu, MD, PhD,
- Maxim N. Artyomov, PhD,
- Anne H. Cross, MD and
- Brian T. Edelson, MD, PhD
- Ekaterina Esaulova, MS*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Claudia Cantoni, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Irina Shchukina, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Konstantin Zaitsev, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Robert C. Bucelli, MD, PhD,
I was asked to participate in an advisory board meeting for MT Pharma prior to the launch of edaravone. This was limited to a single meeting and I have no ongoing ties to MT Pharma.
1) Parents of a family member I care for with Parsonage Turner syndrome, a recurring annual financial gift has been provided to me in hopes that it could be used towards Parsonage Turner research.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I have equity in the Neurology board review website called Neuroquestions, LLC
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gregory F. Wu, MD, PhD,
1. Commercial - Genentech
NONE
Travel - ACTRIMS2020, CMSC 2019
editorial board of N2 - no compensation.
NONE
NONE
NONE
Commercial - Novartis, EMD Serono, GenzymeGovernment - Department of Justice
NONE
NONE
NONE
Commercial - EMD Serono, Biogen, Roche
PI, NIH R01NS083678
NONE
PI, Doris Duke Foundation
NONE
NONE
NONE
NONE
NONE
Government - Department of Justice
- Maxim N. Artyomov, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anne H. Cross, MD and
Commercial Entities: (1) Roche: member scientific advisory board 2010-2019 (2)Genentech: member of scientific advisory board 2015-2020; (3) Biogen: consulting; (4) EMD-Serono: consulting; (5) Genzyme/Sanofi: consulting; (6) Novartis: consulting; (7) Celgene: attendance at advisory board; (8) TG Therapeutics: attendance at advisory board; Non-Profit: (1) Race to Erase MS (formerly Nancy Davis Center Without Walls): reviewing grants, presence at review meetings; (2) National MS Society: speaking at regional meetings in 2018, 2020; (3) Consortium of MS Centers: participation in Board of Director meetings, talks at meetings, current Secretary of Board of Governors of CMSC
NONE
(1) gave talk for EMD-Serono in Stockholm 2019, included travel funded by EMD-Serono; (2) spoke at Genentech meetings (2016 - 2019); (3) research talk at scientific symposium of the Race to Erase MS (Nonprofit).
(1) Brain Pathology,Editorial Board, 2008-ongoing - no compensation (2) Editorial Board, Journal of Neuroimmunology, Editorial Board, 1996- ongoing - no compensation
U.S. patent #15060-630 ÂMethods for simultaneous multi-angular relaxometry of tissue using magnetic resonance imaging
NONE
NONE
(1)Biogen, ad hoc consultant, 2005-2020, (2) Sanofi- Aventis/ Genzyme, ad hoc consultant 2010 -2018 (3) Novartis, ad hoc consultant 2013- 2020; (4) Gerson Lehrman Group Austin Tx,consultant 2009-2019, (5) Guidepoint Global, LLC, New York, New York,consultant, (6) EMD Serono- ad hoc consultant 2012-2020, (7) TG Therapeutics - ad hoc consultant 2019; (8) Genentech - ad hoc consultant 2011-2020, (9) Celgene - ad hoc consultant 2018-2020; (10) At Point of Care - writer and commentator on CME programs - 2018,2019
I gave two talks in 2019 for the Genentech Speakers' bureau, but have since stepped down from that group.
(1) Projects in Knowledge, Livingston NJ 07039- fee for writing (2)Prime Education, Inc, fee for giving CME talk - 2016 & 2017; (3) honoraria for reviewing grants and serving on Scientific Advisory Board for Race To ERASE MS 2016-2019 (this is also disclosed in Sections above; (4) honoraria for reviewing grants for the Conrad N. Hilton Foundation 2018; (5) Board of Governors Member, Consortium of MS Centers 2016 ongoing (now Secretary); (6) WebMD, honoraria for filming and speaking on topics related to MS 2016-2019; (7)PeerView CME: talk at symposium at 2018 annual meeting of CMSC (8) Academic CME, honoraria for CME talk at ACTRIMS 2018, 2019; (9)Potomac Ctr for Medical Education -honoraria for giving 5 CME talks in mostly rural areas about MS in 2019
NONE
(1) Roche site PI for study of ocrelizumab in primary progressive MS (ORATORIO- now in open-label extension called OLE), (2) back-up investigator on a study at our site of ocrelizumab for RRMS (OPERA), began in 2011 and are now in open-label extension, (3) Roche - site co-PI of OBOE - open-label study intended to better understand mechanism of action of drug, (4) Site co-PI for CLOCK-MS study funded by EMD-Serono.
(1)National Institutes of Health NINDS 2PO1 NS059560- 01
NONE
(1) Barnes-Jewish Hospital Foundation, PI, 2005-2019 (2) Conrad N Hilton Foundation 2014-2020
NONE
NONE
NONE
NONE
NONE
NONE
- Brian T. Edelson, MD, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Mallinckrodt LLC (Dr. Edelson is the co-investigator on a grant from this entity awarded to Dr. Chang Liu).
(1) NIH (NIAID), 1 R01 AI113118, Dr. Edelson is PI, 05/05/15-04/30/20 (2) NIH (NIAID), 1 R01 AI132653, Dr. Edelson is PI (multi-PI with Dr. Christina Stallings), 09/24/18-08/31/23 (3) NIH (NINDS), 5 P50 AG005681, Dr. Edelson is the PI on a pilot grant supported by this P50 award, 05/01/19-4/30/20 (4) NIH (NCATS), 5 UL1 TR002345, Dr. Edelson was the PI on a Clinical and Translational Research Funding Program award from this UL1 award, 03/01/18-02/28/19 (5) NIH (NCATS), 5 UL1 TR002345, Dr. Edelson is a co- investigator (PI Dr. Chang Liu) on a Clinical and Translational Research Funding Program award from this UL1 award, 03/01/19- 02/28/20
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Pathology and Immunology (E.E., I.S., K.Z., G.F.W., M.N.A., B.T.E.) and Department of Neurology (C.C., R.C.B., G.F.W., A.H.C.), Washington University School of Medicine, St. Louis, MO; and Computer Technologies Department (K.Z.), ITMO University, St. Petersburg, Russia.
- Correspondence
Dr. Edelson bedelson{at}path.wustl.edu or Dr. Wu wug{at}neuro.wustl.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.